IGM Biosciences, Inc. Retained Earnings
IGM Biosciences, Inc. had Retained Earnings of -$972.35 million as of 2025-06-30, per its 10-Q filed 2025-07-31.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2025-07-31
- 2025-06-30: Retained Earnings (Accumulated Deficit) -$972.35M.
- 2025-03-31: Retained Earnings (Accumulated Deficit) -$1.07B.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$1.02B.
- 2024-09-30: Retained Earnings (Accumulated Deficit) -$980.39M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2025-06-30 | -$972.35M 10-Q · filed 2025-07-31 |
| 2025-03-31 | -$1.07B 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$1.02B 10-Q · filed 2025-07-31 |
| 2024-09-30 | -$980.39M 10-Q · filed 2024-11-08 |
| 2024-06-30 | -$918.96M 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$871.06M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$821.24M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$760.55M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$698.56M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$634.13M 10-Q · filed 2023-05-12 |
| 2022-12-31 | -$574.83M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$522.25M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$464.21M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$405.62M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$353.72M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$303.08M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$258.92M 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$220.20M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$188.56M 10-K · filed 2022-03-29 |
| 2020-09-30 | -$163.94M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$143.67M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$124.83M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$107.20M 10-K · filed 2021-03-30 |
| 2019-09-30 | -$92.39M 10-Q · filed 2019-11-07 |
| 2018-12-31 | -$64.07M 10-K · filed 2020-03-26 |